Fluorescence-based functional assay for Wnt/beta-catenin signaling activity
Aberrant activation of beta-catenin signaling has been implicated in the development of human cancers. As a Wnt signal transducer, beta-catenin forms a complex with the lymphocyte enhancer-binding factor/T cell factor transcription factor and activates downstream targets that promote cell proliferat...
| Publié dans: | BioTechniques. - 1991. - 33(2002), 5 vom: 21. Nov., Seite 1126-8, 1130, 1132 passim |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , , |
| Format: | Article |
| Langue: | English |
| Publié: |
2002
|
| Accès à la collection: | BioTechniques |
| Sujets: | Research Support, Non-U.S. Gov't Technical Report Journal Article CTNNB1 protein, human CTNNB1 protein, mouse Culture Media, Conditioned Cytoskeletal Proteins DNA-Binding Proteins GAL4 protein, S cerevisiae Luminescent Proteins plus... |
| Résumé: | Aberrant activation of beta-catenin signaling has been implicated in the development of human cancers. As a Wnt signal transducer, beta-catenin forms a complex with the lymphocyte enhancer-binding factor/T cell factor transcription factor and activates downstream targets that promote cell proliferation. Here we developed a Wnt-dependent beta-catenin-mediated heterologous transactivation system, which consisted of a chimeric transcription factor constructed by fusing the GAL4 DNA-binding domain with the full-length beta-catenin, and a GAL4-responsive reporter expressing GFP. The chimeric transcription factor was highly unstable and exerted no detectable transactivating effect on the GAL4-responsive reporter. However, lithium and Wnt1 significantly stabilized this chimeric transactivator, indicating that this transactivation system is regulated by beta-catenin in a Wnt-responsive fashion. Thus, this transactivation system could be used as a functional reporter to identify potential upstream factors that deregulate beta-catenin signaling during tumorigenesis, as well as to screen for potential anti-cancer agents that specifically inhibit beta-catenin signaling in human tumors |
|---|---|
| Description: | Date Completed 17.06.2003 Date Revised 28.09.2018 published: Print Citation Status MEDLINE |
| ISSN: | 1940-9818 |